Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
2015 · The Lancet · 1,865 citations
https://doi.org/10.1016/s0140-6736(15)00056-2
J
Julie Fox
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
389
Papers
15.6K
Citations
53
h-index
170
i10-index
Julie Fox is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: HIV/AIDS Research and Interventions & HIV Research and Treatment & HIV/AIDS drug development and treatment. The author has an h-index of 53, co-authored 331 publications.
ORCID: 0000-0002-0583-8019Papers by this author
worksMapping the human genetic architecture of COVID-19
2021 · Nature · 1,104 citations
https://doi.org/10.1038/s41586-021-03767-x
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
2019 · The Lancet · 975 citations
https://doi.org/10.1016/s0140-6736(19)30418-0
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · The Lancet · 556 citations
https://doi.org/10.1016/s0140-6736(21)00149-5
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · The Lancet · 516 citations
https://doi.org/10.1016/s0140-6736(21)00897-7
Whole-genome sequencing reveals host factors underlying critical COVID-19
2022 · Nature · 341 citations
https://doi.org/10.1038/s41586-022-04576-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat